In the past week, MIRM stock has gone up by 12.61%, with a monthly gain of 16.29% and a quarterly surge of 13.66%. The volatility ratio for the week is 6.78%, and the volatility levels for the last 30 days are 4.40% for Mirum Pharmaceuticals Inc The simple moving average for the last 20 days is 14.05% for MIRM stock, with a simple moving average of 39.48% for the last 200 days.
Is It Worth Investing in Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Right Now?
The 36-month beta value for MIRM is also noteworthy at 1.18. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MIRM is 38.04M, and at present, short sellers hold a 17.99% of that float. The average trading volume of MIRM on November 15, 2024 was 371.28K shares.
MIRM) stock’s latest price update
The stock price of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) has surged by 5.33 when compared to previous closing price of 43.92, but the company has seen a 12.61% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-12 that Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben – Vice President, Investor Relations Chris Peetz – Chief Executive Officer Peter Radovich – President & Chief Operating Officer Joanne Quan – Chief Medical Officer Eric Bjerkholt – Chief Financial Officer Conference Call Participants Gavin Clark-Gartner – Evercore ISI. Jessica Fye – JP Morgan Dae Gon Ha – Stifel Brian Skorney – Baird David Lebowitz – Citi Thomas Yip – H.C.
Analysts’ Opinion of MIRM
Many brokerage firms have already submitted their reports for MIRM stocks, with Stifel repeating the rating for MIRM by listing it as a “Buy.” The predicted price for MIRM in the upcoming period, according to Stifel is $48 based on the research report published on April 17, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MIRM reach a price target of $58, previously predicting the price at $60. The rating they have provided for MIRM stocks is “Buy” according to the report published on December 18th, 2023.
JP Morgan gave a rating of “Overweight” to MIRM, setting the target price at $37 in the report published on November 20th of the previous year.
MIRM Trading at 15.49% from the 50-Day Moving Average
After a stumble in the market that brought MIRM to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.98% of gains for the given period.
Volatility was left at 4.40%, however, over the last 30 days, the volatility rate increased by 6.78%, as shares surge +17.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.07% upper at present.
During the last 5 trading sessions, MIRM rose by +12.61%, which changed the moving average for the period of 200-days by +74.83% in comparison to the 20-day moving average, which settled at $40.56. In addition, Mirum Pharmaceuticals Inc saw 56.71% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRM starting from Heron Patrick J, who purchase 115 shares at the price of $37.40 back on Sep 18 ’24. After this action, Heron Patrick J now owns 162,308 shares of Mirum Pharmaceuticals Inc, valued at $4,301 using the latest closing price.
Heron Patrick J, the Director of Mirum Pharmaceuticals Inc, purchase 230 shares at $41.58 during a trade that took place back on Sep 06 ’24, which means that Heron Patrick J is holding 162,193 shares at $9,563 based on the most recent closing price.
Stock Fundamentals for MIRM
Current profitability levels for the company are sitting at:
- -0.3 for the present operating margin
- 0.73 for the gross margin
The net margin for Mirum Pharmaceuticals Inc stands at -0.32. The total capital return value is set at -0.17. Equity return is now at value -38.83, with -14.76 for asset returns.
Based on Mirum Pharmaceuticals Inc (MIRM), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -13.12.
Currently, EBITDA for the company is -136.49 million with net debt to EBITDA at -1.37. When we switch over and look at the enterprise to sales, we see a ratio of 7.5. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In summary, Mirum Pharmaceuticals Inc (MIRM) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
